Evidence map›Paper›PMID 34680796›Full record

ReviewAntibiotics (Basel, Switzerland)2021

Ana C Almeida-Santos, Carla Novais, Luísa Peixe, Ana R Freitas

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 78 citations in OpenAlex.

  1. From predicted bacteriocins to ecological function.Current research in microbial sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Microorganisms · 2026
    Review
  10. Review
  11. Article
  12. Respiratory Microbiome of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025
    Article
  13. Article
  14. Article
  15. Genomic Characterization and Safety Evaluation ofAntibiotics (Basel, Switzerland) · 2025
    Article
  16. Functional Profiling ofMicroorganisms · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ana C Almeida-SantosUCIBIO-Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0001-6711-4780
Carla NovaisUCIBIO-Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-3826-6731
Luísa PeixeUCIBIO-Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0001-5810-8215
Ana R FreitasUCIBIO-Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-7326-4133
Universidade do Porto · PT

Funding

European Regional Development Fund NORTE-01-0145-FEDER-000041Fundação para a Ciência e a Tecnologia UIDB/04378/2020Fundação para a Ciência e a Tecnologia UIDP/04378/2020
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alternatives to antibioticsantimicrobial resistancebacteriocinsenterocinsenterococcigut microbiotamultidrug-resistant infectionsVRE

Identifiers

PMID34680796
PMCPMC8532689
OpenAlexW3205774435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.